CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $83.89M, above the global median of $18.73M
- FinancialsAltman Z-Score 4.05: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.31%Below 5Y avg (1.91%)
Annual Rate
GBP 0.04Paid semi-annual
Payout Ratio
71.2%Moderate
Payback Period
64.4 yr
Last Ex-Dividend
Oct 16, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
231.30MGBP309.00M · vs all stocks (USD)
Trailing P/E
47.86xRevenue (TTM)
89.11MGBP119.04M · vs all stocks (USD)
Profit Margin
5.70%Beta
0.6700xvs all stocks
52-Week Change
28.85%vs all stocks
Forward Annual Dividend Yield
1.31%vs all stocks
Market Capitalization
231.30MGBP309.00M · vs all stocks (USD)
Enterprise Value
243.60MGBP325.42M · vs all stocks (USD)
Trailing P/E
47.86xForward P/E
21.34xPrice to Sales (TTM)
2.60xPrice to Book (MRQ)
2.02xEnterprise to Revenue
2.73xEnterprise to EBITDA
18.93xProfit Margin
5.70%Operating Margin
4.83%Return on Assets (TTM)
2.61%Return on Equity (TTM)
4.46%Revenue (TTM)
89.11MGBP119.04M · vs all stocks (USD)
Revenue per Share (TTM)
1.29GBPUpdated Aug 21, 2026Quarterly Revenue Growth
21.50%Gross Profit (TTM)
51.38MGBP68.63M · vs all stocks (USD)
EBITDA (TTM)
16.58MGBP22.15M · vs all stocks (USD)
Net Income (TTM)
5.08MGBP6.78M · vs all stocks (USD)
Operating Cash Flow (TTM)
11.81MGBP15.78M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
62.80MGBP83.89M · vs all stocks (USD)
Forward Annual Dividend Rate
0.0440GBPUpdated Aug 21, 2026Forward Annual Dividend Yield
1.31%vs all stocks
Trailing Annual Dividend Rate
0.0520GBPUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.55%vs all stocks
5-Year Average Dividend Yield
1.91%vs all stocks
Payout Ratio
71.23%Revenue
89.11MGBPFY2025 · Dec 31, 2025Cost of Goods Sold
37.73MGBPFY2025 · Dec 31, 2025Gross Profit
51.38MGBPFY2025 · Dec 31, 2025Operating Income
6.20MGBP8.28M · vs all stocks (USD)
Pre-tax Income
6.34MGBPFY2025 · Dec 31, 2025Income Tax Expense
1.26MGBPFY2025 · Dec 31, 2025Net Income
5.08MGBPFY2025 · Dec 31, 2025EBIT
7.24MGBPFY2025 · Dec 31, 2025EBITDA (Income Statement)
16.58MGBPFY2025 · Dec 31, 2025Research & Development
651.00KGBPFY2025 · Dec 31, 2025Selling, General & Administrative
14.68MGBPFY2025 · Dec 31, 2025Other Operating Expenses
1.89MGBPFY2025 · Dec 31, 2025Non-operating Interest Income
37.00KGBPFY2025 · Dec 31, 2025Non-operating Interest Expense
898.00KGBPFY2025 · Dec 31, 2025EPS (Basic)
0.0730GBPFY2025 · Dec 31, 2025EPS (Diluted)
0.0730GBPFY2025 · Dec 31, 2025Basic Shares Outstanding
69.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
69.25MSharesFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00GBPFY2025 · Dec 31, 2025Operating Cash Flow
8.23MGBPFY2025 · Dec 31, 2025Free Cash Flow
8.01MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.91MGBPFY2025 · Dec 31, 2025Starting Profit (CF Statement)
6.34MGBPFY2025 · Dec 31, 2025Stock-based Compensation
214.00KGBPFY2025 · Dec 31, 2025Other Non-cash Items
978.00KGBPFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-334.00KGBPFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
1.03MGBPFY2025 · Dec 31, 2025Capital Expenditures
-221.00KGBPFY2025 · Dec 31, 2025Net Intangibles (CF)
-4.02MGBPFY2025 · Dec 31, 2025Net Acquisitions
135.00KGBPFY2025 · Dec 31, 2025Purchase of Investments
-1.44MGBPFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.53MGBPFY2025 · Dec 31, 2025Common Dividends Paid
-3.59MGBPFY2025 · Dec 31, 2025Other Financing Charges
-61.00KGBPFY2025 · Dec 31, 2025Net Financing Cash Flow
-3.63MGBPFY2025 · Dec 31, 2025Shares Outstanding
69.05MSharesUpdated Aug 21, 2026Float Shares
41.14MSharesUpdated Aug 21, 2026% Held by Insiders
27.39%vs all stocks
% Held by Institutions
61.87%vs all stocks
Total Cash (MRQ)
2.91MGBP3.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0420GBPUpdated Aug 21, 2026Total Debt (MRQ)
15.21MGBP20.32M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1328xCurrent Ratio (MRQ)
1.61xBook Value per Share (MRQ)
1.66GBPUpdated Aug 21, 2026Total Assets
158.10MGBP211.21M · vs all stocks (USD)
Total Current Assets
34.23MGBPFY2025 · Dec 31, 2025Total Liabilities
43.56MGBPFY2025 · Dec 31, 2025Total Non-current Assets
123.88MGBPFY2025 · Dec 31, 2025Total Non-current Liabilities
22.36MGBPFY2025 · Dec 31, 2025Total Current Liabilities
21.20MGBPFY2025 · Dec 31, 2025Cash
2.91MGBPFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.91MGBPFY2025 · Dec 31, 2025Accounts Receivable
15.97MGBPFY2025 · Dec 31, 2025Inventory
13.27MGBPFY2025 · Dec 31, 2025Accounts Payable
12.01MGBPFY2025 · Dec 31, 2025Short-term Debt
3.32MGBPFY2025 · Dec 31, 2025Other Current Liabilities
38.00KGBPFY2025 · Dec 31, 2025Long-term Debt
11.89MGBPFY2025 · Dec 31, 2025Common Stock (Book)
13.81MGBPFY2025 · Dec 31, 2025Retained Earnings
5.59MGBPFY2025 · Dec 31, 2025Total Shareholders' Equity
114.54MGBP153.01M · vs all stocks (USD)
52-Week Low
216.00GBXUpdated Aug 21, 202652-Week High
340.00GBXUpdated Aug 21, 202652-Week Change
28.85%vs all stocks
Beta
0.6700xvs all stocks
50-Day MA
332.58GBXUpdated Aug 21, 2026200-Day MA
284.06GBXUpdated Aug 21, 2026Avg 10-Day Volume
360.02KSharesUpdated Aug 21, 2026Avg 30-Day Volume
261.51KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.0700GBPUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.05: safe zoneNotable
Altman Z-Score: 4.05
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $83.89M, above the global median of $18.73MNotable
Levered free cash flow (USD): 83,888,006.152Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Evommune, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
CytoDyn Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule